Identificación de fenotipos y características clínicas del asma en muestra de pacientes atendidos en IPS Centro Neumológico Pulmovida de Barranquilla, entre 2016 y 2023

dc.contributor.advisorMendoza Torres, Evelyn
dc.contributor.advisorPaúl González, Héctor Enrique
dc.contributor.authorCastiblanco Arroyave, Sara Camila
dc.contributor.authorDíaz Ariza, Luis Antonio
dc.coverage.spatialBarranquillaspa
dc.creator.emailluis-diazariza@unilibre.edu.cospa
dc.creator.emailsarac-castiblancoa@unilibre.edu.cospa
dc.date.accessioned2024-07-31T19:55:41Z
dc.date.available2024-07-31T19:55:41Z
dc.date.created2024-06
dc.description.abstractLa fenotipificación del asma en adultos es una tendencia creciente. La de mayor relevancia es la que clasifica la enfermedad de acuerdo con características inmunológicas subyacentes: asma de marcada respuesta inmune tipo 2 (T2 elevada), con predominante respuesta eosinofílica, o asma sin respuesta T2 marcada (T2 baja). Principales referencias sitúan a la primera como la más prevalente donde, además, se puede establecer si existe componente alérgico asociado, con base a niveles de Inmunoglobulina E total (IgE). Se desconoce si dicha prevalencia aplica para Colombia. El objetivo era determinar la prevalencia de fenotipos del asma según su respuesta inmune y posible componente alérgico, junto a características clínicas en una población de Barranquilla, Colombia. Se hizo un estudio observacional, descriptivo, de corte transversal sin intención de asociación, que incluyó a pacientes asmáticos adultos en cualquier clasificación (Step) de tratamiento de un centro neumológico de Colombia. Se estableció la prevalencia de los fenotipos del asma de acuerdo con la respuesta celular (eosinofílico o T2 alto/no eosinofílico o T2 bajo). A los T2 alto, se delimitó predominancia alérgica o no (según resultado de IgE total). Se identificaron las distribuciones según edad, género y grupo etario, sumado a categorización de características clínicas, como antecedentes o comorbilidades y el patrón espirométrico. En conclusión, el asma eosinofílico (T2 alto) fue el fenotipo más prevalente en dicha población Colombiana. El componente alérgico se encontró en la mayoría de los que tenían respuesta T2 alta. El subtipo asmático T2 alto / alérgico, fue el más prevalente (56%).spa
dc.description.abstractenglishThe phenotyping of asthma in adults is a growing trend. The most relevant classification is based on underlying immunological characteristics: asthma with a marked type 2 immune response (high T2), predominantly eosinophilic, or asthma without a marked T2 response (low T2). Major references indicate that the former is the most prevalent, where it is also possible to determine if there is an associated allergic component based on total Immunoglobulin E (IgE) levels. It is unknown whether this prevalence applies to Colombia. The objective was to determine the prevalence of asthma phenotypes according to their immune response and possible allergic component, along with clinical characteristics in a population from Barranquilla, Colombia. An observational, descriptive, cross-sectional study without intention of association was conducted, including adult asthma patients in any treatment classification (Step) from a pulmonary center in Colombia. The prevalence of asthma phenotypes was established according to cellular response (eosinophilic or high T2 / non-eosinophilic or low T2). For those with high T2, allergic predominance was delineated based on total IgE results. Distributions by age, gender, and age group were identified, along with categorization of clinical characteristics such as medical history or comorbidities and spirometric pattern. In conclusion, eosinophilic asthma (high T2) was the most prevalent phenotype in this Colombian population. The allergic component was found in the majority of those with a high T2 response. The high T2 / allergic asthma subtype was the most prevalent (56%).spa
dc.description.sponsorshipUniversidad Libre Seccional Barranquilla -- Facultad de Ciencias de la Salud y Exactas y Naturales -- Especialización en Medicina Internaspa
dc.formatPDFspa
dc.identifier.urihttps://hdl.handle.net/10901/29616
dc.relation.referencesGlobal Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2024. Updated May 2024. Available from: www.ginaasthma.org.spa
dc.relation.referencesWoodruff P, Bhakta N, Ortega VE, Lambrecht B, Fahy J PG. Chapter 60- Asthma: Pathogenesis and Phenotypes. En: Murray and Nadel’s Textbook of Respiratory Medicine. 7th ed. Elsevier; 2022. p. 807-24.spa
dc.relation.referencesThe Global Asthma Report 2022. int j tuberc lung dis. 25 de noviembre de 2022;26(1):1-104.spa
dc.relation.referencesGEMA 5.4. Guía Española para el Manejo del Asma.spa
dc.relation.referencesPopović-Grle S, Štajduhar A, Lampalo M, Rnjak D. Biomarkers in Different Asthma Phenotypes. Genes. 25 de mayo de 2021;12(6):801.spa
dc.relation.referencesHolgate ST, Wenzel S, Postma DS, Weiss ST, Renz H, Sly PD. Asthma. Nat Rev Dis Primers. 10 de septiembre de 2015;1(1):15025.spa
dc.relation.referencesBrusselle GG, Koppelman GH. Biologic Therapies for Severe Asthma. Taichman DB, editor. N Engl J Med. 13 de enero de 2022;386(2):157-71.spa
dc.relation.referencesThomas D, McDonald VM, Pavord ID, Gibson PG. Asthma remission: what is it and how can it be achieved? Eur Respir J. noviembre de 2022;60(5):2102583.spa
dc.relation.referencesPazmiño FA, Navarrete Jiménez ML. Mecanismos inmunológicos implicados en la patología del asma alérgica. Rev Fac Med. 4 de septiembre de 2014;62(2):265-77.spa
dc.relation.referencesMinSalud. 2022. Controla el asma, disfruta la vida. [Internet]. Disponible en: https://www.minsalud.gov.co/Regiones/Paginas/Controla-el-asma,-disfruta-la-vida.aspxspa
dc.relation.referencesChung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. febrero de 2014;43(2):343-73.spa
dc.relation.referencesBakakos P. Asthma: From Phenotypes to Personalized Medicine. JPM. 6 de noviembre de 2022;12(11):1853.spa
dc.relation.referencesAkar-Ghibril N, Casale T, Custovic A, Phipatanakul W. Allergic Endotypes and Phenotypes of Asthma. J Allergy Clin Immunol Pract. febrero de 2020;8(2):429-40.spa
dc.relation.referencesDiamant Z, Vijverberg S, Alving K, Bakirtas A, Bjermer L, Custovic A, et al. Toward clinically applicable biomarkers for asthma: An EAACI position paper. Allergy. 2019;74(10):1835-51.spa
dc.relation.referencesWenzel SE. Severe Adult Asthmas: Integrating Clinical Features, Biology, and Therapeutics to Improve Outcomes. Am J Respir Crit Care Med. 1 de abril de 2021;203(7):809-21.spa
dc.relation.referencesPrice DB, Bosnic-Anticevich S, Pavord ID, Roche N, Halpin DMG, Bjermer L, et al. Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations. Clin Transl Allergy. diciembre de 2019;9(1):41.spa
dc.relation.referencesKerkhof M, Tran TN, Soriano JB, Golam S, Gibson D, Hillyer EV, et al. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. Thorax. febrero de 2018;73(2):116-24.spa
dc.relation.referencesFitzGerald JM, Bleecker ER, Menzies-Gow A, Zangrilli JG, Hirsch I, Metcalfe P, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. The Lancet Respiratory Medicine. enero de 2018;6(1):51-64.spa
dc.relation.referencesFitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. octubre de 2016;388(10056):2128-41.spa
dc.relation.referencesStern J, Pier J, Litonjua AA. Asthma epidemiology and risk factors. Semin Immunopathol. febrero de 2020;42(1):5-15.spa
dc.relation.referencesNtontsi P, Photiades A, Zervas E, Xanthou G, Samitas K. Genetics and Epigenetics in Asthma. IJMS. 27 de febrero de 2021;22(5):2412.spa
dc.relation.referencesShi F, Zhang Y, Qiu C. Gene polymorphisms in asthma: a narrative review. Ann Transl Med. junio de 2022;10(12):711-711.spa
dc.relation.referencesHamilton D, Lehman H. Asthma Phenotypes as a Guide for Current and Future Biologic Therapies. Clinic Rev Allerg Immunol. octubre de 2020;59(2):160-74.spa
dc.relation.referencesNurmagambetov T, Kuwahara R, Garbe P. The Economic Burden of Asthma in the United States, 2008-2013. Ann Am Thorac Soc. marzo de 2018;15(3):348-56.spa
dc.relation.referencesHeaney LG, Perez de Llano L, Al-Ahmad M, Backer V, Busby J, Canonica GW, et al. Eosinophilic and Noneosinophilic Asthma. Chest. septiembre de 2021;160(3):814-30.spa
dc.relation.referencesNanda A, Wasan AN. Asthma in Adults. Medical Clinics of North America. enero de 2020;104(1):95-108.spa
dc.relation.referencesTraidl-Hoffmann C, Zuberbier T, Werfel T, editores. Allergic Diseases – From Basic Mechanisms to Comprehensive Management and Prevention [Internet]. Cham: Springer International Publishing; 2022 [citado 20 de marzo de 2023]. (Handbook of Experimental Pharmacology; vol. 268). Disponible en: https://link.springer.com/10.1007/978-3-030-84048-8spa
dc.relation.referencesHasegawa K, Craig SS, Teach SJ, Camargo CA. Management of Asthma Exacerbations in the Emergency Department. The Journal of Allergy and Clinical Immunology: In Practice. julio de 2021;9(7):2599-610.spa
dc.relation.referencesRoselli D, Lasalvia P, Peña MP, Castañeda C, Virgüez Ó, González A, et al. Perfil clínico y costos directos de la atención de asma en una red de instituciones de salud en Bogotá. rev colomb neumol [Internet]. 3 de diciembre de 2020 [citado 28 de abril de 2023];31(2). Disponible en: https://revistas.asoneumocito.org/index.php/rcneumologia/article/view/420spa
dc.relation.referencesEl-Husseini ZW, Gosens R, Dekker F, Koppelman GH. The genetics of asthma and the promise of genomics-guided drug target discovery. The Lancet Respiratory Medicine. octubre de 2020;8(10):1045-56.spa
dc.relation.referencesGarcía, Gabriel. ALAT: Guía de práctica clínica Latinoamericana de Asma grave. 2020. ALAT.spa
dc.relation.referencesFrati F, Salvatori C, Incorvaia C, Bellucci A, Di Cara G, Marcucci F, et al. The Role of the Microbiome in Asthma: The Gut–Lung Axis. IJMS. 30 de diciembre de 2018;20(1):123.spa
dc.relation.referencesGil Torres, MD. PR. Epidemiología del asma en Colombia. rev colomb neumol [Internet]. 20 de julio de 2015 [citado 11 de marzo de 2023];27(3). Disponible en: https://revistas.asoneumocito.org/index.php/rcneumologia/article/view/78spa
dc.relation.referencesHolgate ST. A Brief History of Asthma and Its Mechanisms to Modern Concepts of Disease Pathogenesis. Allergy Asthma Immunol Res. 2010;2(3):165.spa
dc.relation.referencesTraidl-Hoffmann C, Zuberbier T, Werfel T, editores. Allergic Diseases – From Basic Mechanisms to Comprehensive Management and Prevention [Internet]. Cham: Springer International Publishing; 2022 [citado 20 de marzo de 2023]. (Handbook of Experimental Pharmacology; vol. 268). Disponible en: https://link.springer.com/10.1007/978-3-030-84048-8spa
dc.relation.referencesDrazen J, Bel E. Capítulo 81: Asma. En: Goldman-Cecil Tratado de medicina interna. 26.a ed. Elsevier; 2021. p. 528-37.spa
dc.relation.referencesStikker BS, Hendriks RW, Stadhouders R. Decoding the genetic and epigenetic basis of asthma. Allergy. abril de 2023;78(4):940-56.spa
dc.relation.referencesCasciano J, Krishnan J, Small MB, Li C, Dotiwala Z, Martin BC. Progression to Uncontrolled Severe Asthma: A Novel Risk Equation. J Manag Care Spec Pharm. enero de 2017;23(1):44-50.spa
dc.relation.referencesChen M, Shepard II K, Yang M, Raut P, Pazwash H, Holweg CTJ, et al. Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate-to-severe asthma. Clinical & Experimental Allergy. 2021;51(4):546-55.spa
dc.relation.referencesWenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. mayo de 2012;18(5):716-25.spa
dc.relation.referencesKuruvilla ME, Lee FEH, Lee GB. Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease. Clinic Rev Allerg Immunol. 1 de abril de 2019;56(2):219-33.spa
dc.relation.referencesOppenheimer J, Hoyte FCL, Phipatanakul W, Silver J, Howarth P, Lugogo NL. Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions. Annals of Allergy, Asthma & Immunology. agosto de 2022;129(2):169-80spa
dc.relation.referencesIsrael E, Reddel HK. Severe and Difficult-to-Treat Asthma in Adults. Drazen JM, editor. N Engl J Med. 7 de septiembre de 2017;377(10):965-76.spa
dc.relation.referencesO’Neill S, Sweeney J, Patterson CC, Menzies-Gow A, Niven R, Mansur AH, et al. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. Thorax. 1 de abril de 2015;70(4):376-8.spa
dc.relation.referencesRussell RJ, Brightling C. Pathogenesis of asthma: implications for precision medicine. Clinical Science. 30 de junio de 2017;131(14):1723-35.spa
dc.relation.referencesPapi A, Brightling C, Pedersen SE, Reddel HK. Asthma. The Lancet. febrero de 2018;391(10122):783-800.spa
dc.relation.referencesLambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. enero de 2015;16(1):45-56.spa
dc.relation.referencesFuchs O, Bahmer T, Rabe KF, von Mutius E. Asthma transition from childhood into adulthood. Lancet Respir Med. marzo de 2017;5(3):224-34.spa
dc.relation.referencesAl-Muhsen S, Johnson JR, Hamid Q. Remodeling in asthma. J Allergy Clin Immunol. septiembre de 2011;128(3):451-62; quiz 463-4.spa
dc.relation.referencesJackson DJ, Johnston SL. The role of viruses in acute exacerbations of asthma. J Allergy Clin Immunol. junio de 2010;125(6):1178-87; quiz 1188-9.spa
dc.relation.referencesAnnunziato F, Romagnani C, Romagnani S. The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol. marzo de 2015;135(3):626-35.spa
dc.relation.referencesRicciardolo FLM, Sprio AE, Baroso A, Gallo F, Riccardi E, Bertolini F, et al. Characterization of T2-Low and T2-High Asthma Phenotypes in Real-Life. Biomedicines. 13 de noviembre de 2021;9(11):1684.spa
dc.relation.referencesRobinson D, Humbert M, Buhl R, Cruz AA, Inoue H, Korom S, et al. Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. febrero de 2017;47(2):161-75.spa
dc.relation.referencesCiprandi G, Tosca MA, Silvestri M, Ricciardolo FLM. Inflammatory biomarkers for asthma endotyping and consequent personalized therapy. Expert Rev Clin Immunol. julio de 2017;13(7):715-21.spa
dc.relation.referencesJonckheere AC, Bullens DMA, Seys SF. Innate lymphoid cells in asthma: pathophysiological insights from murine models to human asthma phenotypes. Curr Opin Allergy Clin Immunol. febrero de 2019;19(1):53-60.spa
dc.relation.referencesSamitas K, Zervas E, Gaga M. T2-low asthma: current approach to diagnosis and therapy. Curr Opin Pulm Med. enero de 2017;23(1):48-55.spa
dc.relation.referencesSprio AE, Carriero V, Levra S, Botto C, Bertolini F, Di Stefano A, et al. Clinical Characterization of the Frequent Exacerbator Phenotype in Asthma. J Clin Med. 14 de julio de 2020;9(7):2226spa
dc.relation.referencesLouis R, Satia I, Ojanguren I, Schleich F, Bonini M, Tonia T, et al. European Respiratory Society Guidelines for the Diagnosis of Asthma in Adults. Eur Respir J. 15 de febrero de 2022;2101585.spa
dc.relation.referencesAriza LAD, Arroyave CSC, Meléndez RJV, Arroyave SCC, Osorio-Llanes E, Mendoza-Torres E. No todo lo que sibila es asma: revisión de tema. Revista Colombiana de Neumología. 1 de junio de 2023;35(1):11-21.spa
dc.relation.referencesTay TR, Choo XN, Yii A, Chung KF, Chan YH, Wong HS, et al. Asthma phenotypes in a multi-ethnic Asian cohort. Respiratory Medicine. octubre de 2019; 157:42-8.spa
dc.relation.referencesUllemar V, Magnusson PKE, Lundholm C, Zettergren A, Melén E, Lichtenstein P, et al. Heritability and confirmation of genetic association studies for childhood asthma in twins. Allergy. febrero de 2016;71(2):230-8.spa
dc.relation.referencesChung KF. Personalised medicine in asthma: time for action: Number 1 in the Series “Personalised medicine in respiratory diseases” Edited by Renaud Louis and Nicolas Roche. Eur Respir Rev. 30 de septiembre de 2017;26(145):170064spa
dc.relation.referencesNewby C, Heaney LG, Menzies-Gow A, Niven RM, Mansur A, Bucknall C, et al. Statistical Cluster Analysis of the British Thoracic Society Severe Refractory Asthma Registry: Clinical Outcomes and Phenotype Stability. Brock G, editor. PLoS ONE. 24 de julio de 2014;9(7): e102987.spa
dc.relation.referencesLefaudeux D, De Meulder B, Loza MJ, Peffer N, Rowe A, Baribaud F, et al. UBIOPRED clinical adult asthma clusters linked to a subset of sputum omics. Journal of Allergy and Clinical Immunology. junio de 2017;139(6):1797-807.spa
dc.relation.referencesCunha F, Amaral R, Jacinto T, Sousa-Pinto B, Fonseca JA. A Systematic Review of Asthma Phenotypes Derived by Data-Driven Methods. Diagnostics. 2 de abril de 2021;11(4):644.spa
dc.relation.referencesMaspero J, Pavie J, Torres-Duque CA, Montero-Arias F, Cerino-Javier R, Rovira F, et al. Toward a better understanding of severe asthma phenotypes in Latin America: results from the PREPARE study. Curr Med Res Opin. abril de 2023;39(4):627-38.spa
dc.relation.referencesSonia M. Restrepo Gualteros MD, Milena Villamil Osorio MD, Martínez CER. Fenotipos del asma en Pediatría. Revista Colombiana de Neumología [Internet]. 20 de julio de 2015 [citado 6 de junio de 2024];27(3). Disponible en: https://revistas.asoneumocito.org/index.php/rcneumologia/article/view/83spa
dc.relation.referencesGuzmán MC, de Vivero M, Gil I, Marrugo V, Mercado D, Zakzuk J, et al. [Characterization of asthma phenotypes in children of the tropics]. Rev Alerg Mex. 1 de febrero de 2024;71(1):74.spa
dc.relation.referencesMaia LP, Cunha TM, Santos PS, Martins MM, Briza P, Ferreira F, et al. Exploring Inflammatory Asthma Phenotypes: Proteomic Signatures in Serum and Induced Sputum. Int J Mol Sci. 20 de marzo de 2024;25(6):3501.spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2spa
dc.rights.licenseAtribución-NoComercial-SinDerivadas 2.5 Colombiaspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/spa
dc.subjectAsmaspa
dc.subjectFenotipospa
dc.subjectAsma T2 altospa
dc.subjectAsma T2 bajospa
dc.subjectIgE total séricaspa
dc.subject.lembAsmaspa
dc.subject.lembFenotipospa
dc.subject.lembInmunoglobulina Espa
dc.subject.subjectenglishAsthmaspa
dc.subject.subjectenglishPhenotypespa
dc.subject.subjectenglishT2 high asthmaspa
dc.subject.subjectenglishT2 low asthmaspa
dc.subject.subjectenglishTotal serum IgEspa
dc.titleIdentificación de fenotipos y características clínicas del asma en muestra de pacientes atendidos en IPS Centro Neumológico Pulmovida de Barranquilla, entre 2016 y 2023spa
dc.title.alternativeIdentification of phenotypes and clinical characteristics of asthma in a sample of patients treated at Centro Neumológico Pulmovida in Barranquilla, between 2016 and 2023spa
dc.type.coarhttp://purl.org/coar/resource_type/c_7a1fspa
dc.type.driverinfo:eu-repo/semantics/bachelorThesisspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localTesis de Especializaciónspa

Archivos

Bloque original

Mostrando 1 - 2 de 2
Cargando...
Miniatura
Nombre:
CASTIBLANCO.pdf
Tamaño:
805.56 KB
Formato:
Adobe Portable Document Format
Descripción:
Archivo del trabajo de grado para descargar
Cargando...
Miniatura
Nombre:
FORMULARIO AUTORIZACIÓN.pdf
Tamaño:
10.99 MB
Formato:
Adobe Portable Document Format
Descripción:
Autorización para la publicación

Bloque de licencias

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción: